Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The role of glucagon in the pathophysiology of diabetes has long been recognized, although its approved clinical use has so far been limited to the emergency treatment of severe hypoglycaemia. A novel use of glucagon as intermittent mini‐boluses is proposed in the dual‐hormone version (insulin and glucagon) of the external artificial pancreas. Short‐term studies suggest that the incorporation of glucagon into artificial pancreas systems has the potential to further decrease hypoglycaemic risk and improve overall glucose control; however, the potential long‐term safety and benefits also need to be investigated given the recognized systemic effects of glucagon. In the present report, we review the available animal and human data on the physiological functions of glucagon, as well as its pharmacological use, according to dosing and duration (acute and chronic). Along with its main role in hepatic glucose metabolism, glucagon affects the cardiovascular, renal, pulmonary and gastrointestinal systems. It has a potential role in weight reduction through its central satiety function and its role in increasing energy expenditure. Most of the pharmacological studies investigating the effects of glucagon have used doses exceeding 1 mg, in contrast to the mini‐boluses used in the artificial pancreas. The available data are reassuring but comprehensive human studies using small but chronic glucagon doses that are close to the physiological ranges are lacking. We propose a list of variables that could be monitored during long‐term trials of the artificial pancreas. Such trials should address the questions about the risk–benefit ratio of chronic glucagon use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · cited 2×
“Glucagon is the principal stimulator of hepatic glucose production; firstly it activates glycogenolysis followed by gluconeogenesis while suppressing glycogenesis and glycolysis through key rate limiting enzymes of these processes [42,44,45].”
BackgroundBonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“Recently, sodium-glucose co-transporter 2 (SGLT-2)mediated glucose sensing by the α cells has been described; SGLT-2 is expressed in pancreatic α but not β cells and exerts an inhibitory effect on glucagon release.(24) The main modulators of glucagon secretion are summarized in Figure 1.”
BackgroundAbnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626 · cited 1×
“6 mmol/L in healthy controls), both groups achieved similar glucagon values (124 and 126 ng/L, respectively).(38) In type 2 diabetes, relative hyperglucagonaemia (fasting and postprandial) has also been reported early in the course of the disease at the stage of impaired glucose tolerance.”
BackgroundHome Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433 · cited 1×
“Recurrent events alter the sympatho-adrenal and neuronal stimulation of glucagon release in response to subsequent hypoglycaemia.(31,32) Studies in people with type 1 diabetes either report a blunted glucagon response or an insufficient increase with shorter”
BackgroundA Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
Rizza, R. A. (2010) · Diabetes · doi:10.2337/db10-1032 · Cited by 367 · cited 1×
“In type 2 diabetes, relative hyperglucagonaemia (fasting and postprandial) has also been reported early in the course of the disease at the stage of impaired glucose tolerance.(39,40) Whether this defect in glucagon suppression plays a significant role in the progression to diabetes is still debatable.”
BackgroundHypoglycemia-associated autonomic failure in advanced type 2 diabetes.
Segel, S. A., Paramore, D. S., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.3.724 · Cited by 337
The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272 · cited 4×
“Longuet et al.(66) have shown the need for an intact glucagon receptor (GCGR) by demonstrating”
BackgroundResultInfluentialGlucagon physiology and pathophysiology
Sherwood, L. M., Parris, E. E., & Unger, R. H. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108192850806 · Cited by 267
Cardiovascular effects of glucagon in man
Parmley, W. W., Glick, G., & Sonnenblick, E. H. (1968) · New England Journal of Medicine · doi:10.1056/nejm196807042790103 · Cited by 246
Zhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., Braun, M., Brereton, M., Collins, S., Galvanovskis, J., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.014 · Cited by 225
Haidar, A., Legault, L., Dallaire, M., Alkhateeb, A., Coriati, A., Messier, V., Cheng, P., Millette, M., Boulet, B., & Rabasa-Lhoret, R. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121265 · Cited by 167
Self-citationHyperglucagonemia increases resting metabolic rate in man during insulin deficiency
NAIR, K. S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-896 · Cited by 141
Leong, K. S., Walker, A. B., Martin, I., Wile, D., Wilding, J., & MacFarlane, I. A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01169.x · Cited by 140
Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
Siafarikas, A., Johnston, R. J., Bulsara, M. K., O’Leary, P., Jones, T. W., & Davis, E. A. (2012) · Diabetes Care · doi:10.2337/dc11-2010 · Cited by 120 · cited 3×
“The glucagon response to hypoglycaemia decreases gradually with time; a pathological process described in patients with longstanding type 2 diabetes(28) and earlier, within the first year of diagnosis, in patients with type 1 diabetes.(29) Glucagon response to other stimuli”
BackgroundResultInfluentialRenard, E., Farret, A., Kropff, J., Bruttomesso, D., Messori, M., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0008 · Cited by 104
Uebanso, T., Taketani, Y., Yamamoto, H., Amo, K., Ominami, H., Arai, H., Takei, Y., Masuda, M., Tanimura, A., Harada, N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022976 · Cited by 99
Taborsky, G. J. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400607 · Cited by 96
Simsek, Y., Karaca, Z., Tanriverdi, F., Unluhizarci, K., Selcuklu, A., & Kelestimur, F. (2015) · Clinical Endocrinology · doi:10.1111/cen.12528 · Cited by 64
Diabetes Research in Children Network (DirecNet) Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2298 · Cited by 61
Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12627 · Cited by 39
Hashimoto, T., Adachi, K., Ishimura, N., Hirakawa, K., Katsube, T., Kurotani, A., Hattori, S., & Kinoshita, Y. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01148.x · Cited by 38
Cited by
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Castle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
“While no major side effects have been reported in the short-term clinical trials aside from mild nausea and occasional vomiting, glucagon safety in the setting of chronic use still needs to be established.(99)”
InfluentialSelf-citationHemodynamic Effects of Glucagon: A Literature Review
Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00050 · Cited by 68
Novel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Metadata
- Authors
- Taleb, N., Haidar, A., Messier, V., Gingras, V., Legault, L., & Rabasa‐Lhoret, R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-11-09
- Volume
- 19
- Issue
- 1
- Pages
- 13-23
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2528767427
- Cited by
- 59
- References
- 24
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.